Background Radiological exposure associated with transcatheter aortic valve implantation (TAVI) is unknown and might impact on broadening indications to lower risk patients. Radiological exposure of TAVI patients and its predictors are herein reported.
Methods Radiological exposure derived from exams/ procedures performed within 30 days preceding/following TAVI were acquired and converted into effective-dose. Total effective-dose was defined as the sum of each single dose derived from diagnostic/therapeutic sources. Univariable and multivariable analyses were performed to recognize correlates of exposure.
Results Seventy-five patients aged 82.6 W 6.0 years with a median Euroscore II 3.6 [IQR 1.93-6.65] were analysed. Median total effective-dose was 41.39 mSv .88], with TAVI accounting for 47% of it. Age (coefficient S0.031, 95% CI S0.060 to S0.002; P U 0.031) and previous history of cerebrovascular accidents (CVA; coefficient S0.545; 95% CI S1.039 to S0.010; P U 0.046) resulted as inversely correlated to total effective-dose
Introduction
The introduction of techniques allowing the percutaneous replacement of a stenotic aortic valve represented one of the major advancements of interventional cardiology in recent years.
Transcatheter aortic valve implantation (TAVI) was originally offered as an alternative to medical therapy in elderly patients at extreme or high surgical risk. Its huge therapeutic potential allowed the demonstration of, on short-term outcomes, a reduction in mortality in nonoperable patients and noninferiority to surgery in high-risk patients. 1, 2 Justified by that initial evidence, an exponential increase in procedures was observed, 3 this was associated with a progressive widening of the indications, resulting in a concomitant decrease in patient's complexity. 4 -6 Thus, future adoption of this technique as the therapy of choice for an all-comer population with severe aortic stenosis seems to be a potential perspective, 7 also justified by the great advances obtained in the optimization of procedural outcomes. 8 Nonetheless, almost no relevance has been given so far to the amount and potential long-term effects of X-ray exposure during TAVI, an aspect considered of little clinical significance, due to the presumed low risk of clinically evident effects.
Few retrospective analyses report on the procedural radiological exposure of those patients, neglecting that a complex preprocedural work-up and postprocedural phase might significantly impact on the total exposure. 9, 11 In light of a more widespread use of TAVI in younger patients, radiological exposure cannot be disregarded any longer, needs to be provided as a part of the information given to patients and has to play a role in the decision between TAVI vs. traditional surgical approaches.
Thus, the aim of this article is to describe the total radiological exposure observed in a contemporary series of TAVI patients and to recognize predictors of increased exposure.
Methods

Patient population
All patients with severe symptomatic aortic valve stenosis with complete data on the fluoroscopic exposition who have been treated with TAVI procedures at our Institution between 1 January 2015 and 31 May 2016 were considered in the present analysis. Clinical data and procedural details were prospectively collected according to Swiss TAVI Registry requirements, and analysed. Data on radiological exposure derived from all exams/procedures performed within 30 days preceding/following the implant procedure have been acquired from the on-site data system. Written informed consent for the TAVI procedure and data acquisition were signed by all patients.
Patient workflow
Before final candidacy for TAVI, surgery or medical therapy, each patient has to undergo a definite preprocedural work-up in order to confirm the clinical indication, plan the procedure and foresee potential challenges. Transthoracic and transoesophageal echocardiography as well as a diagnostic coronary angiography and a contrastenhanced computed tomography (CT) scan are performed in all suitable patients before heart team discussion. Additional radiological examinations/procedures (e.g. chest X-ray, adjunctive CT scan, unplanned coronary angiography, pacemaker implantation, etc.) are performed both preprocedurally and postprocedurally, when deemed clinically necessary.
In patients with an estimated glomerular filtration rate less than 40 ml/kg/min, angiographic examinations are reduced to the strictly necessary, withholding angio CT scans in the vast majority of cases and echo data are used to plan the procedure.
Coronary angiography
Coronary angiography is performed through the radial access with a set of three cine projections for the right coronary artery and six for the left. When TAVI is considered as an option, aortography (LAO 308) and an angiography in the AP projection of the iliofemoral vessel is also performed. When revascularization is deemed necessary, percutaneous coronary interventions (PCI) are performed on the same or on a staged procedure. Both for cine and fluoroscopy frame, the rate is set at 15 frame/s and all images are acquired on a Philips Allura Clarity X-ray unit (Philips, Best, The Netherlands). Regular calibration of the radiological equipment was performed.
Computed tomography scan
Preprocedural CT imaging is performed on a 128 detectors dual-source CT (Somatom Force; Siemens Healthcare, Forchheim, Germany) to evaluate the anatomy of the aortic annulus and access vessels using a prespecified protocol. 12 An ECG-triggered high-pitch spiral acquisition is performed (250 ms gantry rotation, 66 ms temporal resolution, 2 Â 192 Â 0.6 collimation, tube voltage 120 kV, tube current 350-500 mA depending on weight). Scan direction is craniocaudal from above the aortic arch to below the hip. After a test bolus to evaluate the contrast agent transit time, 80 ml of dye is injected in an antecubital vein with a flow rate of 5 ml/s. Images are reconstructed using a slice thickness of 0.6 mm, and an increment of 0.4 mm.
On the basis of CT scan data, annular dimensions are measured and navigability of the ileofemoral arteries is ascertained. The angiographic projection showing the three hinge points of the aortic cusps is searched and suggested to the interventional cardiologist as a potential implant view. 12 Transcatheter aortic valve implantation procedure All procedures have been performed in a hybrid room with an Allura Philips fluoroscopy system by a team of four operators with expertise on coronary and structural interventions. Each operator had a personal background of more than 200 TAVI implants. Procedures were performed with a standard fluoroscopy-guided implant procedure. Fluoroscopic acquisition was set at 15 f/s. The reliability of the implant view predicted with CT scan was ascertained with a cine aortography. In case of unsatisfactory alignment, another implant view by means of multiple angiographies was chosen.
Release of retrievable valves was performed during continuous fluoro imaging or cine recordings with repeated dye injections to constantly monitor the valve position. For balloon expandable valves, balloon inflation and deflation were recorded with cine.
Effective-dose estimation
The equation ED ¼ OQ Â CF, where OQ ¼ operational quantity, and CF ¼ conversion factor were used for the estimation of the effective-dose.
To convert the dose area product data provided by angiographic equipment, the CF of 0.24 mSv/Gy cm 2 published by Karambatsakidou et al. 10 was used, whereas for the dose length product conversion the CFs published by Deak et al. were used. 13 CF used to calculate effective-dose for traditional X-ray examinations were derived from Heron.
14 Total effective-dose was defined as the sum of each single effective-dose derived from diagnostic or therapeutic sources in the 30 days preceding or following the TAVI procedure.
Statistical analysis
Data are described as mean and standard deviation or the median and interquartile range (IQR) if continuous, and counts and percentage if categorical. Generalized linear regression models to identify correlates of total effective-dose were used; given the skewed distribution, the latter was log-transformed. All noncollinear variables with a P less than 0.1 at the univariable analysis were included in a multivariable model. The choice between collinear predictor was based on clinical knowledge. A model fit was graphically assessed by using residuals. A two-sided P value less than 0.05 was considered statistically significant. Stata 14 (StataCorp, College Station, Texas, USA) was used for computations.
Results
Patient population
Seventy-five patients with a mean age of 82.6 AE 6.0 years and an intermediate-to-low surgical risk (median Euroscore II 3.6 [IQR 1.93-6.65]) treated with TAVI at our site were evaluated. Baseline clinical and echocardiographic characteristics are reported in Table 1 .
All except one patient underwent a preprocedural coronary angiography during the work-up phase: in 10 cases (13.3%) coronary angiography was followed by PCIs whereas in one patient, a balloon aortic valvuloplasty was performed as a bridge to TAVI. In 66 cases (88%), a contrast-enhanced CT angiography was performed.
The vast majority of TAVI were performed through a percutaneous transfemoral approach (92%). In about twothirds of cases, a self-expandable valve was implanted. An overall low complication rate was observed with one intraprocedural death. In two cases, surgical repair of the femoral artery was needed; no peripheral interventions to repair access site complications, that could have significantly increased exposure were performed. Table 2 reports on the details related to the TAVI procedure. During the postprocedural phase, a repeated angiographic examination was deemed necessary in two patients, whereas a percutaneous mitral valve repair and a percutaneous mitral valve dilatation were performed in two distinct patients. Table 3 shows the radiological exposure derived from diagnostic sources, therapeutic procedures and TAVI implantation.
Radiological exposure
The median total effective-dose of patients treated with TAVI was 41.39 mSv [IQR 27.93-60.88]. Distribution of total radiological exposure was skewed with 86% receiving less than 100 mSv and 10 patients showing an exposure greater than 100 mSv (Fig. 1) .
TAVI implant resulted as the prevalent source of radiological exposure, with a median effective-dose of 16.11 mSv [IQR 10.54-27.70] per procedure, accounting for almost half of the total exposure.
Contrast-enhanced cardiac and angio CT scans were performed in 88% of patients, whereas other CT scans were needed in the preprocedural or postprocedural phase in 22.6% of patients (cerebral CT scan in 15, Data regarding radiological exposure derived from pace maker implantations as well as from standard radiological exams are reported in Table 3 , whereas Fig. 2 describes the relative impact on total exposure according to the source.
During hospitalization or at 1-month follow-up, none of the patients showed signs suggestive of deterministic effects (skin erythema, irreversible skin damage, chest hair loss or cataract) related to the periprocedural or intraprocedural radiological exposure. Correlates of total radiological exposure Table 4 reports the results of the univariable and multivariable analysis. Male sex (coefficient 0.383, 95% CI 0.022-0.745; P ¼ 0.010), and reduced left ventricular ejection fraction (LVEF < 50%; coefficient 0.497, 95% CI 0.117-0.876; P ¼ 0.011) were associated with increased total additive effective-dose (log-transformed), whereas age (per year) was inversely correlated
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Discussion
The main findings of our study are as follows:
(1) Multiple radiological exams and procedures are responsible for the exposure observed in TAVI patients, with implant procedure being the prominent source. (2) Age is inversely related to the radiological exposure, with younger patients receiving higher doses.
Our article reports not only the intraprocedural data but also the detailed quantification of the total TAVIrelated burden of X-ray exposure including the preprocedural work-up, the implant and the postprocedural phase. In addition, predictors of increased exposure were identified.
Our data revealed that a significant X-ray exposure of patients treated with TAVI derives from multiple sources. A median of 16.1 mSv was delivered to patients during the implant, accounting for almost 50% of the total exposition and in line with previous reports. 10 Putting those data into perspective, this exposure is comparable with the average 19.4 mSv individual cumulative dose of nuclear plant employees received over their entire career. 15 Such a significant exposure represents a clear indication for the development and the implementation of institutional low-dose protocols to minimize procedural exposure leading to a significant reduction in exposure during percutaneous coronary interventions. 16 Nonetheless, although being the most important source of X-ray, TAVI implant represents just one of different sources to which patients are exposed during the preprocedural work-up or the postimplant phase. A median additive effective-dose of 41.39 mSv was measured in our population with almost 15% of patients exposed to a total dose exceeding 100 mSv. This massive exposure has been recognized to induce deterministic effects and to significantly increase by 10% the relative risk of solid cancers and by 19% of leukaemia in a large dosimetric study. 15 Thus, optimization of the radiological exposure should not be limited to the implant procedure but extended to the entire preprocedural work-up and postprocedural phase. In fact, common practice is to evaluate all patients undergoing TAVI with both a coronary angiogram and an ECGgated angio CT for annular measurement. As evident from our data, only less than 60% of patients had a known history of coronary artery disease, whereas the remaining could have been screened for by careful analysis of the angio CT scan, scheduling for invasive angiography only those with a clear suspicion of significant coronary disease. Accurate analysis of CT scan data has shown a high sensitivity and negative predictive value in excluding obstructive coronary artery disease, thus avoiding the need for preprocedural angiographic examination in TAVI candidates with nonobstructive disease at preprocedural CT scan. 17, 18 Not surprisingly, patient's age resulted inversely correlated with total exposure, meaning that younger patients are those receiving greater doses. Our data demonstrate that a reduction of 10 years in age corresponds to a 30% increase of the log-dose, thus with a potential detrimental long-term effect for younger patients. This evidence might be a consequence of several concomitant factors such as the desire of obtaining a more extended revascularization prior to the TAVI procedure, the possibility to perform multiple percutaneous procedures, or a preserved renal function thus allowing a more liberal adoption of preprocedural CT scans or angiographic examinations. Nonetheless, because of the retrospective nature of our analysis, any potential implication remains speculative.
Risk of fatal and nonfatal malignancies associated with radiological exposures in TAVI might represent a negligible hazard whether observed from a local standpoint. Nonetheless, if considered from a continental or global perspective, tangible effects of this exposure might become already manifest at the present stage, with a current volume of TAVI procedures estimated to be of more than 70 000 so far 19 and with a trend expected to skyrocket in the next future.
Limitations
The retrospective nature of our work does not allow the drawing of definite conclusions but data have to be considered as hypothesis-generating and the small sample size might impact on dose estimations.
Moreover, evaluation of the effective dose for TAVI procedures is based on several assumptions and is thus associated with uncertainties in dose estimates, so this should be considered as approximations to guide clinical decision. Finally, although this article aims at sensitizing the cardiological community on the patient's related risks associated with radiological exposure, evaluation of the professional exposure is beyond our scope.
In conclusion, this is the first report giving a total estimation of the radiological exposure and of the exposure-related risk of fatal lung cancer derived from a contemporary TAVI series.
Present data allow the rationalizing of exposure of TAVI patients, to extend information given to patients prior to the procedure in terms of additive radiological risk, as well as to increase the awareness of the cardiological community towards this significant source of exposure aiming at protecting patients and health professionals.
